TKT and chronic myelogenous leukemia, BCR-ABL1 positive: <b>Conclusions:</b> Intermediate <b>A</b> emerges as a significant anti-CML candidate exhibiting potent cytotoxic, apoptotic, and moderate ABL TK inhibitory activity, together with a favorable selectivity profile.